Biocon Share Price Target 2025 to 2040, Detailed Analysis

Here, we are going to share Biocon Share Price Target 2025, 2026, 2027, 2028, 2030, 2035, 2040 on the basis of its fundamental and technical analysis.

Biocon Ltd. is a prominent biopharmaceutical company headquartered in Bengaluru, India. Development, and manufacture of generic active pharmaceutical ingredients (APIs) and biopharmaceuticals.

The company specializes on oncology, immunology, and diabetes, and uses its experience in biosimilars, generics, and new biologics to achieve globally growth.

Biocon Share Key Information

Biocon Business Sector

Biocon Limited is a biopharmaceutical company that specializes in developing, manufacturing, and distributing biologics, biosimilars, and generic formulations. The company’s key areas are:

1. Biologics and Biosimilars: Biocon is a leading provider of biosimilars in therapeutic areas such as diabetes, oncology, and autoimmune diseases.
2. Generics: Biocon produces generic formulations, which are distributed globally, making essential medicines more accessible across developed and emerging markets.
3. Research and Development (R&D): Biocon makes major investments in R&D for innovative biologics, medication formulations, and advanced therapy options, which contribute to advances in immunology, cancer, and metabolic disorders.

Board Members

• Kiran Mazumdar Shaw – Executive Chairperson
• Siddharth Mittal – CEO & Managing Director
• Ravi Mazumdar – Non-Executive Director
• Bobby Kanubhai Parikh – Non-Executive Independent Director
• Eric Mazumdar – Non-Executive Director
• Naina Lal Kidwai – Lead Independent Director
• Rekha Mehrotra Menon – Non-Executive Independent Director
• Nicholas Robert Haggar – Non-Executive Independent Director
• Atul Dhawan – Non-Executive Independent Director

Biocon Share Quarterly Results

Also Read

Canara Bank Share Price Target 2025 to 2040, Detailed Analysis

Biocon Company Profits and Losses

Biocon Share Price Target 2025-2040

Also Read

Bharat Petroleum Corporation (BPCL) Share Price Target 2025 to 2040, Detailed Analysis

Biocon Share Price Target 2025

Based on the 2025 forecast, the initial target of Biocon share can could be ₹359 and by the end of the year, the share price target is estimated to reach ₹330.

Biocon Share Price Target 2026

Based on the 2026 forecast, the initial target of Biocon share can could be ₹329 and by the end of the year, the share price target is estimated to reach ₹301.

Biocon Share Price Target 2027

Based on the 2027 forecast, the initial target of Biocon share can could be ₹300 and by the end of the year, the share price target is estimated to reach ₹271.

Also Read

Apollo Hospitals Enterprise Share Price Target 2025 to 2040, Detailed Analysis

Biocon Share Price Target 2028

Based on the 2028 forecast, the initial target of Biocon share can could be ₹271 and by the end of the year, the share price target is estimated to reach ₹242.

Biocon Share Price Target 2029

Based on the 2029 forecast, the initial target of Biocon share can could be ₹242 and by the end of the year, the share price target is estimated to reach ₹209.

Biocon Share Price Target 2030

Based on the 2030 forecast, the initial target of Biocon share can could be ₹210 and by the end of the year, the share price target is estimated to reach ₹183.

Biocon Share Price Target 2035

Based on the 2035 forecast, the initial target of Biocon share can could be ₹96.35 and by the end of the year, the share price target is estimated to reach ₹88.67.

Also Read

Alok Industries Share Price Target 2025 to 2040, Detailed Analysis

Biocon Share Price Target 2040

Based on the 2040 forecast, the initial target of Biocon share can could be ₹50.96 and by the end of the year, the share price target is estimated to reach ₹42.10.

Biocon Shareholding Pattern

Biocon Company Competitors

• Aurobindo Pharma
• Abbott India
• Glenmark Pharma
• Ipca Laboratories
• Ajanta Pharma
• Piramal Pharma
• Suven Pharma

Bull Case of Biocon (Reasons to Invest)

1. Market Leadership and Product Expansion: Biocon’s extensive market presence and varied biopharma portfolio position it well for future growth, particularly as worldwide demand for biosimilars grows.
2. Favorable Regulatory Support: Supportive regulatory frameworks in key markets like the U.S. and EU could expedite approvals, reducing time-to-market for biosimilar drugs.

Bear Case of Biocon (Risks Involved)

1. Regulatory and Competitive Risks: The biopharmaceutical sector is subject to tight regulations, and any delays in medication approvals may have an impact on Biocon’s market position and profitability.
2. Operational Challenges: Biocon has faced operational issues such as delays and product recalls, which have affected stock performance.

Also Read

Hikal Ltd Share Price Target 2025 to 2040, Detailed Analysis

Biocon Share Price Target: FAQ